Form 4: Teva CFO Converts RSUs to Ordinary Shares

Teva Pharmaceutical Industries' CFO, Eliyahu Sharon Kalif, converted restricted share units into ordinary shares, increasing direct beneficial ownership.

Summary

• Eliyahu Sharon Kalif, Teva's EVP and Chief Financial Officer, reported changes in beneficial ownership of Teva Pharmaceutical Industries Ltd. securities.
• On March 3, 2026, Kalif acquired 49,800 Ordinary Shares through the vesting and conversion of Restricted Share Units (RSUs).
• Following this transaction, Kalif directly beneficially owned 107,278 Ordinary Shares.
• On the same date, Kalif acquired an additional 141,478 Ordinary Shares through the vesting and conversion of RSUs.
• This resulted in a total direct beneficial ownership of 248,756 Ordinary Shares after this specific transaction.
• The RSUs converted were part of grants from March 3, 2023, and performance-based awards earned on January 27, 2026, which subsequently vested on March 3, 2026.
• The Ordinary Shares may be represented by American Depositary Shares (ADSs), each currently representing one Ordinary Share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting the routine vesting of executive equity compensation rather than a discretionary investment or divestment decision. It's a positive sign of executive retention and performance criteria being met, but not a strong indicator of new company developments.

Positives

• Increased direct beneficial ownership of Ordinary Shares by a key executive, signaling confidence in the company's long-term prospects.
• The vesting of Restricted Share Units indicates the satisfaction of both performance and time-based criteria, reflecting successful achievement of compensation targets.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly conversions of equity compensation, are common in the pharmaceutical industry as executives realize value from long-term incentive plans. This specific filing reflects a routine compensation event rather than a discretionary open-market purchase or sale, which typically carries stronger signals about management's view on the company's immediate prospects.

Comparison to Industry Standards

• This filing details a standard equity compensation vesting and conversion event for a senior executive.
• Such transactions are typical across large pharmaceutical companies like Pfizer, Novartis, and Merck, where executive compensation packages often include significant RSU components designed to align management incentives with long-term shareholder value.
• The volume of shares acquired is consistent with a senior executive's compensation structure at a company of Teva's size and market capitalization.

Stakeholder Impact

• Shareholders: The conversion of RSUs into ordinary shares increases the executive's direct stake, potentially aligning interests with long-term shareholder value.
• Employees: The vesting of RSUs demonstrates the company's commitment to its executive compensation structure, which can positively influence employee morale and retention.

Next Steps

• 49,802 Restricted Share Units are scheduled to vest on March 3, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting and conversion of Restricted Share Units into ordinary shares. It does not provide new fundamental information about Teva's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not signal a discretionary buy or sell decision by the insider. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions rather than this specific insider filing.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Beneficial Ownership, Restricted Share Units, RSU Conversion, CFO, Eliyahu Sharon Kalif, Equity Compensation